The role of NT-proBNP in high-risk cardiovascular patients for long-term prognosis

doi:10.3969/j.issn.1673-8640.2014.10.007

Abstract

Abstract:

Objective To investigate the role of N-terminal B-type natriuretic peptide (NT-proBNP) level for predicting cardiovascular death events in patients with chest distress and chest pain. Methods A total of 288 patients who were going to emergency with chest distress and chest pain were enrolled. The cardiac troponin T, NT-proBNP, C-reactive protein, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoprotein A, lipoprotein(a), creatine kinase and creatine kinase-MM were determined. The statistical methods contained t test, rank sum test and Chi-square test. Logistic regression analysis and receiver operating characteristic (ROC) curve analysis were performed. Resutls The serum NT-proBNP in the cardiovascular death event follow-up group for 3 years was higher than that without events (P<0.001). Logistic regression analysis showed that NT-proBNP can be as the prediction risk factor for cardiovascular death events, and the odds ratio was 1.97 [95% confidence interval (CI): 1.14-3.39, P=0.015]. Among the 4 groups which were classified by the quarter level of NT-proBNP, the level of NT-proBNP can also predict the readmission to hospitals in the follow-ups. The level of NT-proBNP was related with ages. The ROC curve showed that the area under the curve (AUC) of NT-proBNP was 0.714 (95%CI: 0.504-0.925), which can be as a predictive parameter for cardiovascular death events. Conclusions The level of NT-proBNP before the treatment can be used to predict the occurrence of cardiovascular death events in high-risk cardiovascular patients.

Key words: N-terminal B-type natriuretic peptide, Follow-up, Prognosis

CLC Number:

R446.1

MO Huifang, WU Jiong, SONG Binbin, ZHANG Chunyan, WANG Beili, LIU Xiaowen, GUO Wei, PAN Baishen.. The role of NT-proBNP in high-risk cardiovascular patients for long-term prognosis[J]. , 2014, 29(10): 1013-1018.

References

[1] Lopez AD, Murray CC. The global burden of disease, 1990-2020 [J]. Nat Med, 1998, 4(11):1241-1243.
[2] Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain[J]. Nature, 1988, 332(6159):78-81.
[3] Stein BC, Levin RI. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease[J]. Am Heart J, 1998, 135(5 Pt 1): 914-923.
[4] 童华诚,郭玉军,李玲,等.B型钠尿肽及N端B型钠尿肽原水平与心力衰竭患者心功能的关系[J].检验医学,2006,21(1):58-60.
[5] 伍树芝.血清NT-proBNP测定在心力衰竭患者中的应用价值[J].检测医学,2010,25(10):753-755.
[6] 王跃荣,张栋梁,李岚,等.慢性心力衰竭患者氨基末端B型钠尿肽与心肌肌钙蛋白Ⅰ水平分析[J].检验医学,2011,26(7):433-435.
[7] Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations[J]. Lancet, 2000, 355(9210):1126-1130.
[8] Martinez-Rumayor A, Richards AM, Burnett JC, et al. Biology of the natriuretic peptides[J]. Am J Cardiol, 2008, 101(3A): 3-8.
[9] Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction[J]. Am Heart J, 1998, 135(5 Pt 1): 825-832.
[10] Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure[J]. N Engl J Med, 2002, 347(3): 161-167.
[11] Manzano-Fernández S, Januzzi JL, Boronat-Garci&#x0dbc0;&#x0dd61; M, et al. Impact of kidney dysfunction on plasma and urinary N-terminal pro-B-type natriuretic peptide in patients with acute heart failure[J]. Congest Heart Fail, 2010, 16(5):214-220.
[12] Svensson P, de Faire U, Niklasson U, et al. Plasma NT-proBNP concentration is related to ambulatory pulse pressure in peripheral arterial disease[J]. Blood Press, 2005, 14(2):99-106.
[13] 朱笑频,王成刚.NT-proBNP和cTnI联合检测在急诊心力衰竭患者诊治中的应用[J].检测医学,2013,28(1):30-32.
[14] 袁锦可.血清和肽素在扩张型心肌病心力衰竭患者诊断及治疗中的作用[J].检验医学,2013,28(7):563-566.
[15] 伍树芝,邓胜,秦伟国,等.联合检测NT-proBNP、H-FABP和cTnI对老年重症心力衰竭患者的临床价值[J].检验医学,2014,29(4):312-318.
[16] McLean AS, Huang SJ, Nalos M, et al. The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients[J]. Crit Care Med, 2003, 31(11): 2611-2618.
[17] Melki D, Lind S, Agewall S, et al. Prognostic value of combining high sensitive troponin T and N-terminal pro B-type natriuretic peptide in chest pain patients with no persistent ST-elevation[J]. Clin Chim Acta, 2012, 413(9-10):933-937.
[18] Cappellin E, Gatti R, Antonelli G, et al. Natriuretic peptide fragments as possible biochemical markers of hypertension in the elderly[J]. J Cardiovasc Med (Hagerstown), 2013, 14(4): 308-313.
[19] Theuns DA, Smith T, Szili-Torok T, et al. Prognostic role of high-sensitivity C-reactive protein and B-type natriuretic peptide in implantable cardioverter-defibrillator patients[J]. Pacing Clin Electrophysiol, 2012, 35(3): 275-282.
[20] Shah MR, Califf RM, Nohria A, et al. The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure[J]. J Card Fail, 2011, 17(8): 613-621.
[21] Anand IS, Rector TS, et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial[J]. Circ Heart Fail, 2011, 4(5):569-577.